These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24144311)

  • 1. Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?
    Firkin F
    Leuk Lymphoma; 2014 May; 55(5):977-8. PubMed ID: 24144311
    [No Abstract]   [Full Text] [Related]  

  • 2. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
    Au WY; Lang BH; Fong BM; Mao KJ; Tam S
    Leuk Lymphoma; 2014 May; 55(5):1184-5. PubMed ID: 23964647
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
    Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
    [No Abstract]   [Full Text] [Related]  

  • 4. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Lam MS; Ignoffo RJ
    Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
    [No Abstract]   [Full Text] [Related]  

  • 5. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
    Kuriyama K
    Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
    [No Abstract]   [Full Text] [Related]  

  • 6. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Galm O; Fabry U; Osieka R
    Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758
    [No Abstract]   [Full Text] [Related]  

  • 7. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
    Gupta S; Bagel B; Gujral S; Subramanian PG; Khattry N; Menon H; Nair R
    Leuk Lymphoma; 2012 Nov; 53(11):2192-4. PubMed ID: 22452590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
    Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
    Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Barbey JT; Soignet S
    Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
    [No Abstract]   [Full Text] [Related]  

  • 11. Does arsenic trioxide impact fertility?
    Stein EM; Tallman MS
    Leuk Lymphoma; 2012 Nov; 53(11):2099-100. PubMed ID: 22524541
    [No Abstract]   [Full Text] [Related]  

  • 12. Scientists explore use of arsenic in therapy.
    Miller M
    J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
    Huff J; Waalkes M; Nyska A; Chan P
    J Natl Cancer Inst; 1999 Oct; 91(19):1690-1. PubMed ID: 10511603
    [No Abstract]   [Full Text] [Related]  

  • 14. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
    Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT
    Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 16. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
    Unnikrishnan D; Dutcher JP; Varshneya N; Lucariello R; Api M; Garl S; Wiernik PH; Chiaramida S
    Blood; 2001 Mar; 97(5):1514-6. PubMed ID: 11222403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic: a new place?
    Vincent PC
    Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
    [No Abstract]   [Full Text] [Related]  

  • 18. Arsenic compound approved as cancer chemotherapy agent.
    Miller JL
    Am J Health Syst Pharm; 2000 Nov; 57(21):1940, 1942. PubMed ID: 11094644
    [No Abstract]   [Full Text] [Related]  

  • 19. Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
    Kulkarni UP; Selvarajan S; Fouzia NA; Lionel S; Nair SC; Balasubramanian P; Mani T; Abraham A; George B; Mathews V
    Blood Cancer J; 2023 Jun; 13(1):94. PubMed ID: 37349334
    [No Abstract]   [Full Text] [Related]  

  • 20. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
    Au WY; Tam S; Kwong YL
    Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.